Revolution Medicines (RVMD) reported Phase 3 results for daraxonrasib in previously treated metastatic pancreatic cancer that Wall Street analysts are calling "unprecedented." Median overall survival was 13.2 months vs. 6.7 months for chemotherapy (HR 0.40, p<0.0001). The drug met all primary and secondary endpoints. No drug has previously demonstrated an overall survival benefit greater than one year in a Phase 3 trial for pancreatic cancer. RVMD shares surged in premarket trading.

Revolution also began dosing patients in RASolute 303, a Phase 3 trial of daraxonrasib as first-line treatment for metastatic pancreatic cancer earlier this month, and has a clinical collaboration with Bristol Myers Squibb combining daraxonrasib with navlimetostat.

Replimune (REPL) shares fell more than 19% on Friday following the second CRL for RP1. The company said it will lay off staff and scale back U.S. manufacturing. A Type A meeting with the FDA is expected within 30 days.

Foundayo (orforglipron) enters its second full week of commercial availability. Early prescription data will be the first competitive signal against Novo's oral Wegovy.

Revolution Medicines Regulatory Filing: The company plans to submit data to global regulators including the FDA. Given the magnitude of the survival benefit, expect a priority review designation. Full data will be presented at a major oncology conference in 2026.

M&A Speculation: Revolution Medicines has been on acquisition target lists for months. This data will intensify interest from companies building oncology franchises (Gilead, Merck, AstraZeneca, BMS). Revolution's market cap will need to be watched closely.

RASolute 303 (First-Line PDAC): Dosing began in early April. If daraxonrasib shows similar benefit in untreated patients, the commercial opportunity expands dramatically.

RAS(ON) Doublet (RASolute 309): Planned for H2 2026. Combining daraxonrasib with zoldonrasib (RAS G12D-selective inhibitor) could further extend survival.

Foundayo Week 2: Lilly's oral GLP-1 continues its retail pharmacy rollout. Initial TRx data expected in the coming weeks.

What Happened: Revolution Medicines reported topline results from the Phase 3 RASolute 302 trial evaluating daraxonrasib as monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The trial was a global, randomized, controlled study comparing once-daily oral daraxonrasib to investigator's choice of intravenous chemotherapy. The results met all primary and secondary endpoints. Based on the first interim analysis, all PFS and OS endpoint results are considered final.

The Data: In the intent-to-treat population, daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy, a hazard ratio of 0.40 (p<0.0001). That represents a 60% reduction in risk of death and a 6.5-month improvement in median survival. The drug also met its progression-free survival endpoint. Daraxonrasib was generally well tolerated with a manageable safety profile and no new safety signals. The study enrolled patients across a wide range of RAS variants as well as patients without an identified RAS mutation.

The Pipeline: Revolution is building a franchise around RAS-targeted oncology. In addition to the RASolute 302 readout, the company began dosing patients in RASolute 303 (first-line metastatic PDAC) in early April. RASolute 305 is the first Phase 3 trial for zoldonrasib (RAS G12D-selective) in first-line metastatic PDAC. RASolute 309, a doublet combination of zoldonrasib plus daraxonrasib, is planned for H2 2026. The company also has a clinical collaboration with Bristol Myers Squibb evaluating daraxonrasib plus navlimetostat (PRMT5 inhibitor) in pancreatic cancer patients with RAS mutations and MTAP deletions.

Executive Impact: CEO Mark Goldsmith called the results "unprecedented," noting no drug has previously shown an OS benefit greater than one year in a Phase 3 pancreatic cancer trial. Revolution plans to submit data to global regulators and present detailed findings at a major oncology conference this year. RAS mutations occur in more than 90% of pancreatic cancers, making the addressable population essentially the entire disease. The survival benefit is large enough to support both accelerated and traditional approval pathways. Revolution has been a top acquisition target for months, and this data will put a floor under its valuation. The company also has daraxonrasib programs in non-small cell lung cancer, adding pipeline breadth beyond PDAC.

Now: Foundayo (orforglipron) Week 2 of commercial availability

Now: Revolution Medicines preparing regulatory submission for daraxonrasib

April: Heart Rhythm 2026 conference

April: Novo Nordisk Wegovy HD U.S. launch continues

April 14: AlzeCure Pharma presentation at Redeye Healthcare Day (Stockholm)

Late April: Pharma Partnering US Summit (San Diego)

May 2026: Replimune Type A meeting with FDA expected